Medicaid supplemental rebate agreement

Bayer Healthcare Pharmaceuticals Inc. has been awarded contract X043687 by the New York Department of Health, effective July 1, 2026, through June 30, 2029. The three-year contract carries a cumulative value of $0.00, indicating either a data entry discrepancy or a non-monetary agreement structure. As the prime contractor, Bayer Healthcare Pharmaceuticals Inc. will deliver pharmaceutical products and related healthcare services to support the Department of Health's operational and programmatic objectives within New York State.

While specific product categories, therapeutic areas, and places of performance are not detailed in the available contract documentation, the scope of work aligns with pharmaceutical supply and distribution consistent with Bayer's healthcare portfolio. The contract term extends across a standard three-year performance period, providing the state with a defined service delivery framework. Further details regarding annual value breakdowns, specific deliverables, and performance metrics would typically be documented in supplemental contract specifications and statements of work maintained by the New York Department of Health.